Get the Stockscreener App
56.25
5.10%
-3.02
After Hours:
56.25
Monopar Therapeutics Inc stock is traded at $56.25, with a volume of 260.79K.
It is down -5.10% in the last 24 hours and up +0.05% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
See More
Previous Close:
$59.27
Open:
$60.01
24h Volume:
260.79K
Relative Volume:
1.39
Market Cap:
$376.82M
Revenue:
-
Net Income/Loss:
$-13.72M
P/E Ratio:
-28.32
EPS:
-1.9861
Net Cash Flow:
$-12.20M
1W Performance:
-14.15%
1M Performance:
+0.05%
6M Performance:
-30.21%
1Y Performance:
+51.37%
1-Day Range:
$54.21
$62.04
1-Week Range:
$54.21
$66.00
52-Week Range:
$28.40
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
56.25 | 397.05M | 0 | -13.72M | -12.20M | -1.9861 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Morgan Stanley | Overweight |
| Nov-14-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-25 | Initiated | Leerink Partners | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR) - The Globe and Mail
Saturn V, Xiaoying Tian report 345,626 MNPR shares (5.20%) — MNPR - Stock Titan
Monopar Buy Rating Reiterated on Advancing ALXN1840 Profile and De-Risked Regulatory Path; $104 Price Target Unchanged - TipRanks
Is Monopar Therapeutics (MNPR) Undervalued After Q1 2026 EPS Bea - GuruFocus
Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Monopar Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Monopar (NASDAQ: MNPR) ends Q1 with $137.5M cash and funds through 2027 - Stock Titan
Monopar Therapeutics 1Q 2026: Revenue ($3.93M), Net income ($3.89M), EPS ($0.46) — 10-Q Summary - TradingView
Monopar Therapeutics Reports Q1 2026 Financial Results and Updates on ALXN1840 Development for Wilson Disease - Quiver Quantitative
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Monopar Therapeutics reports Q1 2026 net loss $3.9M, cash $137.5M; NDA on track for mid-2026 - TradingView
Cash runway to 2027 as Monopar (NASDAQ: MNPR) readies ALXN1840 - Stock Titan
Biotech Monopar readies Wilson disease drug filing, funded into 2027 - Stock Titan
Monopar Therapeutics stock (US6093601054): Clinical-stage biotech focused on oncology innovations - AD HOC NEWS
Adage (MNPR) reports 424,195 shares, including 115,000 warrant shares - Stock Titan
Monopar Therapeutics stock (US6093601054): Shares up 3% at $65.52 - AD HOC NEWS
TradingKey - TradingKey
The long term thesis for Monopar Therapeutics (MNPR) in plain sight (Smart Money Outflows) 2026-05-08Long Setup - newser.com
Behavioral Patterns of MNPR and Institutional Flows - Stock Traders Daily
Number of shareholders of Monopar Therapeutics Inc – MUN:1IY0 - TradingView
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
[ARS] Monopar Therapeutics SEC Filing - Stock Titan
[DEF 14A] Monopar Therapeutics Definitive Proxy Statement - Stock Titan
(MNPR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MNPR (Monopar Therapeutics Inc.) slips 2.56% after Q4 2025 earnings miss on larger than expected per share loss.ROIC - Xã Thanh Hà
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON) - The Globe and Mail
MNPR Stock Price, Quote & Chart | MONOPAR THERAPEUTICS INC (NASDAQ:MNPR) - ChartMill
Monopar Therapeutics stock maintained at Buy by Lake Street on trial data - Investing.com Canada
BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $104 - Moomoo
Monopar Therapeutics stock maintained at Buy by BTIG on trial data - Investing.com Canada
Monopar Reports Phase 3 Data Showing ALXN1840 Provides Greater Neurologic Benefit Versus Standard of Care in Wilson Disease Patients - Minichart
ALXN1840 Poised to Redefine Wilson Disease Treatment Standards: Phase 3 Success, De-Risked Profile, and Buy Rating Justification - TipRanks
Monopar Highlights Strong Phase 3 Data for ALXN1840 - TipRanks
Monopar (MNPR) unveils Phase 3 ALXN1840 neurologic gains and plans mid-2026 NDA - Stock Titan
Lake Street Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - MSN
Monopar Therapeutics (MNPR) Shows Promising Results in Wilson Di - GuruFocus
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 - The Manila Times
Monopar Therapeutics Reports Positive Phase 3 Trial Results for ALXN1840 in Wilson Disease Patients at AAN Annual Meeting 2026 - Quiver Quantitative
Wilson disease study: 9% worsened on ALXN1840 vs 25% on standard care - Stock Titan
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Monopar Therapeutics (MNPR) Stock Sector Perform (Weakens) 2026-04-16High Volume Stocks - Xã Vĩnh Công
How (MNPR) Movements Inform Risk Allocation Models - Stock Traders Daily
Chardan Capital Reaffirms Buy Rating on MNPR with $100 Price Tar - GuruFocus
Monopar Therapeutics (NASDAQ:MNPR) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Is Monopar Therapeutics Inc a momentum stock2026 Earnings Surprises & Weekly Top Gainers Trade List - baoquankhu1.vn
Is Monopar Therapeutics Inc stock technically oversold2026 Risk Factors & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Q1 EPS Estimate for Monopar Therapeutics Boosted by Analyst - defenseworld.net
Monopar Therapeutics Inc (MNPR) Gets a Buy from JonesTrading - The Globe and Mail
Brookline Capital Markets Forecasts MNPR Q1 Earnings - MarketBeat
Gains Report: Will Monopar Therapeutics Inc benefit from sector rotationQuarterly Trade Review & Long Hold Capital Preservation Plans - baoquankhu1.vn
Trading Systems Reacting to (MNPR) Volatility - Stock Traders Daily
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):